Pfizer deal a spark for M&A, or just fuel for an empty pipeline? Analysts try to read the tea leaves

Pfizer’s $2.3 billion buyout of immuno-oncology biotech Trillium, which spent most of 2019 in penny-stock territory, has tongues wagging about whether this will prove the biotech M&A push many want from a sluggish 2021.